Display options
Cite
Kume H, Kawai T, Nagata M, et al. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2014;3(2):303-307doi: 10.3892/mco.2014.469.
Kume, H., Kawai, T., Nagata, M., Azuma, T., Miyazaki, H., Suzuki, M., Fujimura, T., Nakagawa, T., Fukuhara, H., & Homma, Y. (2015). Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Molecular and clinical oncology, 3(2), 303-307. https://doi.org/10.3892/mco.2014.469
Kume, Haruki, et al. "Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer." Molecular and clinical oncology vol. 3,2 (2015): 303-307. doi: https://doi.org/10.3892/mco.2014.469
Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H, Homma Y. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol. 2015 Mar;3(2):303-307. doi: 10.3892/mco.2014.469. Epub 2014 Dec 01. PMID: 25798258; PMCID: PMC4360872.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 Mar;3(2):303-307. doi: 10.3892/mco.2014.469. Epub 2014 Dec 01.

Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer.

Molecular and clinical oncology

Haruki Kume, Taketo Kawai, Masayoshi Nagata, Takeshi Azuma, Hideyo Miyazaki, Motofumi Suzuki, Tetsuya Fujimura, Tohru Nakagawa, Hiroshi Fukuhara, Yukio Homma

Affiliations

  1. Department of Urology, The University of Tokyo Hospital, Tokyo 113-8655, Japan.

PMID: 25798258 PMCID: PMC4360872 DOI: 10.3892/mco.2014.469

Abstract

This study was conducted with the aim to investigate the feasibility of intermittent treatment with docetaxel chemotherapy for castration-resistant prostate cancer (CRPC). A total of 51 men with CRPC received docetaxel at 75 mg/m

Keywords: castration-resistant prostate cancer; docetaxel; intermittent therapy

References

  1. N Engl J Med. 2004 Oct 7;351(15):1502-12 - PubMed
  2. Cancer. 2008 Jan 15;112(2):326-30 - PubMed
  3. Cancer Manag Res. 2013 Oct 14;5:357-65 - PubMed
  4. N Engl J Med. 2004 Oct 7;351(15):1513-20 - PubMed
  5. Int Urol Nephrol. 2011 Dec;43(4):1081-7 - PubMed
  6. Jpn J Clin Oncol. 2008 May;38(5):365-72 - PubMed
  7. Int J Clin Oncol. 2009 Apr;14(2):130-5 - PubMed
  8. Urology. 2011 Mar;77(3):682-7 - PubMed

Publication Types